Valeritas (NSDQ:VLRX) topped sales and earnings expectations on Wall Street this week with its second-quarter financial results. The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year. Earnings per share were […]
Ocular Therapeutix beats The Street with Q2 results
Shares in Ocular Therapeutix (NSDQ:OCUL) rose this week after the company topped expectations on Wall Street with its second-quarter financial results. The Bedford, Mass.-based company posted a net loss of -$13.8 million on sales of $648,000 for the three months ended June 30, representing sales growth of 48% compared with the same period last year. Earnings […]
Tandem reels in $115m from public offering
Tandem Diabetes Care (NSDQ:TNDM) said today that it raised roughly $115 million from an underwritten public offering. The San Diego, Calif.-based company offered 3,508,770 shares of its common stock at $28.50 apiece. Underwriters fully exercised an option to buy 526,315 additional shares of common stock, Tandem noted. Also today, the company announced that results from the […]
Report: Smiths may abandon talks of merger with ICU Medical
Smiths Group (LON:SMIN) may walk away from talks of a $9 billion merger of its healthcare division with ICU Medical (NSDQ:ICUI), Sky News reported this week. The two groups began talks more than two months ago, but Smiths is reportedly leaning towards a decision to abandon negotiations. Talks of a potential merger have sparked interest by Baxter to pursue […]
Mylan lowers outlook after Q2 earnings, sales miss estimates
Shares in Mylan (NSDQ:MYL) fell today after the pharmaceutical company missed expectations on Wall Street with its second-quarter financial results. The Canonsburg, Penn.-based company posted profits of $37.5 million, or 7¢ per share, on sales of $2.8 billion for the three months ended June 30, representing a bottom-line loss of -87.4% on a sales loss of […]
Senseonics launches Eversense implantable glucose monitor
Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S. The Germantown, Md.-based company also touted that it won coverage for its CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey. Senseonics’ 90-day, implantable CGM won FDA approval in June this year. […]
Credence MedSystems raises $13m to support syringe systems
Credence MedSystems said today that it closed a $12.8 million Series B round to help support the commercialization of its Companion Syringe system. The company’s components combine with existing syringes to create a product that protects users against accidental needlestick injuries and creates a more user-friendly drug injector, according to Credence. “This investment comes at […]
Frequency Therapeutics launches clinical trial for hearing loss drug
Frequency Therapeutics said today that the first patients have been treated in a Phase I/II clinical trial to assess its first-in-class drug candidate for hearing restoration. The 24-patient trial is slated to include people with stable sensorineural hearing loss. Participants will receive an injection of Frequency’s FX-322 or a placebo in one ear, with a follow-up […]
Researchers use microparticles for targeted delivery of brain cancer therapy
A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to […]
Glaukos inks R&D deal for glaucoma therapy
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. According to the terms of the agreement, DWTI is slated […]
